Could less chemo be better after stem cell transplants?

NCT ID NCT07193420

Not yet recruiting Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a lower dose of the chemotherapy drug cyclophosphamide can reduce side effects after a half-matched stem cell transplant for blood cancers. The standard dose often causes complications, so researchers want to see if a lower dose works just as well. The study will follow 180 adults for two years to compare survival, relapse rates, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cyclophosphamide (a chemotherapy drug)
What this could lead to: If successful, a lower dose of cyclophosphamide could reduce side effects and improve survival without severe complications after stem cell transplants.
What could go wrong: This is an early-stage trial with only 180 participants, so results may not apply to everyone. Lowering the dose might also reduce its effectiveness in preventing graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD - GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD - GRAFT-VERSUS-HOST DISEASE HAPLOIDENTICAL STEM CELL TRANSPLANTATION HSCT

Contacts and locations

Locations

Saint Antoine Hospital - Hematology Department

Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.